SecBot SecBot
Insider Cluster (3 insiders) ·Filed Aug 20, 2026

ADPT

Adaptive Biotechnologies Corp
NEUTRAL
Impact 4/10
Horizondays Processed2mo ago
Insider cluster: 2 insiders, $8.2M total
Actionable Insight • Neutral

CEO Robins' $6.82M sale is notable in absolute terms but represents only 0.2% of market cap, below the 0.5% threshold for significant concern. The sales follow option exercises, typical of pre-planned diversification. Monitor for any Form 4 filings in the next 30 days showing continued selling without option exercise—that would be a stronger bearish signal.

DirectionNeutral
Confidencemedium
Horizondays
Latest settled — T+20d ⚠ clustered
ADPT ▲ +7.20% at T+20d
NEUTRAL call +7.20% · α vs SPY +7.72% · entry $25.99 → $27.86
Next anchor: T+60d in 17d
Latest observation: T+45 -15.29% FF3 residual α
Entry = T+0 close
Aug 20, 2026
via day close
T+1d
-1.69%
call -1.69% · α -1.40%
$25.55
settled 2mo ago
T+5d
-3.08%
call -3.08% · α -3.55%
$25.19
settled 2mo ago
T+20d
+7.20%
call +7.20% · α +7.72%
$27.86
settled 6w ago
T+60d
Pending
in 17d

Price Chart

Loading chart...

Executive Summary

ADPT CEO Chad Robins and two directors sold a total of $8.19M in open-market stock over two days, with the CEO alone selling $6.82M. The sales are tied to option exercises, but the open-market dispositions are substantial relative to the $4.1B market cap (0.2%).

Key Financial Metrics

Direction
selling
Total Value
$8.2M
Insiders
3

Key Facts

  • CEO Chad Robins sold 278,472 shares at $24.48 for $6.82M on 2026-08-18
  • Director Peter Neupert sold 40,000 shares at $25.10 for $1.00M on 2026-08-17
  • Director Robert Hershberg sold 15,000 shares at $24.39 for $366K on 2026-08-18
  • Total open-market sales: $8.19M, representing ~0.2% of $4.1B market cap
  • All sales were preceded by option exercises at $6.32-$6.55 per share, locking in profits

Financial Impact

Total insider sales of $8.19M, or ~0.2% of market cap

insider ownership

Risk Factors

  • CEO selling $6.82M in open market could signal peak valuation view
  • Director Neupert sold $1M, adding to insider selling pressure
  • Insider sales may accelerate if stock continues to rise

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ADPT-1787263289043
28 reports for ADPT
Performance horizon
45% Hit rate @ T+20 5 of 11 directional calls Went positive at some point 7 of 11 best @ T+60▲ +56.41%May 5, 2026
Filters
Rows
Reports for ADPT — sortable, filterable
TypeNow
Oct 6, 2026
21d ago
144
NEUTRAL ★ 2/10
$26.28awaiting T+20—$27.66 (+5.25%)
Oct 5, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$26.90awaiting T+20—$27.66 (+2.83%)
Sep 25, 2026
4w ago
Press Release
BULLISH ★ 6/10
$29.43 $25.51▼ −13.32%▼ −11.84%$27.66 (−6.01%)
Sep 18, 2026
5w ago
Insider Cluster
BEARISH ★ 5/10
$27.86 $23.95▲ +14.03%▲ +13.13%$27.66 (+0.72%)
Aug 20, 2026
9w ago
Insider Cluster
NEUTRAL ★ 4/10
$25.99 $27.86▲ +7.20%▲ +7.72%$27.66 (+6.43%)
Aug 19, 2026
9w ago
Insider Cluster
BEARISH ★ 5/10
$25.44 $28.55▼ −12.22%▼ −12.22%$27.66 (−8.73%)
Aug 18, 2026
10w ago
144
NEUTRAL ★ 3/10
$25.49 $26.68▲ +4.67%▲ +6.19%$27.66 (+8.51%)
Aug 17, 2026
10w ago
144
BEARISH ★ 4/10
$24.56 $27.67▼ −12.66%▼ −13.97%$27.66 (−12.62%)
Jul 29, 2026
12w ago
Institutional Cluster
BEARISH ★ 4/10
$24.18 $26.44▼ −9.35%▼ −5.38%$27.66 (−14.39%)
Jul 23, 2026
13w ago
Insider Cluster
NEUTRAL ★ 4/10
$22.27 $25.99▲ +16.70%▲ +13.08%$27.66 (+24.20%)
Showing 10 of 28

US Market Status

Market Closed — Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 20, 2026